Over the last 7 days, the Healthcare Services industry has dropped 1.4%, driven by Concord Healthcare Group declining 9.6%. Meanwhile, Sinopharm Group actually outperformed within the industry, gaining 7.8% in the last week. The industry has fallen 29% in the last year. Earnings are forecast to grow by 15% annually.
Has the Hong Kong Healthcare Services Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Tue, 13 Aug 2024 | HK$230.8b | HK$829.0b | HK$12.7b | 10.8x | 18.2x | 0.3x |
Thu, 11 Jul 2024 | HK$240.3b | HK$817.7b | HK$12.5b | 10.7x | 19.3x | 0.3x |
Sat, 08 Jun 2024 | HK$264.6b | HK$821.7b | HK$12.5b | 12.3x | 21.1x | 0.3x |
Mon, 06 May 2024 | HK$255.9b | HK$822.5b | HK$12.5b | 12.1x | 20.4x | 0.3x |
Wed, 03 Apr 2024 | HK$225.8b | HK$821.2b | HK$12.7b | 11.6x | 17.8x | 0.3x |
Fri, 01 Mar 2024 | HK$247.0b | HK$814.9b | HK$11.8b | 14.3x | 21x | 0.3x |
Sun, 28 Jan 2024 | HK$233.6b | HK$819.9b | HK$12.1b | 14.8x | 19.4x | 0.3x |
Tue, 26 Dec 2023 | HK$235.2b | HK$820.2b | HK$12.5b | 15.1x | 18.9x | 0.3x |
Thu, 23 Nov 2023 | HK$259.3b | HK$817.0b | HK$12.3b | 16x | 21.1x | 0.3x |
Sat, 21 Oct 2023 | HK$268.4b | HK$801.3b | HK$12.3b | 13.2x | 21.9x | 0.3x |
Mon, 18 Sep 2023 | HK$286.0b | HK$806.7b | HK$12.7b | 13.2x | 22.4x | 0.4x |
Wed, 16 Aug 2023 | HK$285.8b | HK$775.0b | HK$11.3b | 10.6x | 25.3x | 0.4x |
Fri, 14 Jul 2023 | HK$327.0b | HK$809.1b | -HK$57,853,067.00 | 10.9x | -5653x | 0.4x |
Sun, 11 Jun 2023 | HK$315.3b | HK$775.3b | HK$684.9m | 13.2x | 460.4x | 0.4x |
Tue, 09 May 2023 | HK$336.0b | HK$798.7b | HK$1.3b | 11.2x | 263x | 0.4x |
Thu, 06 Apr 2023 | HK$334.1b | HK$799.8b | HK$1.6b | 16.6x | 207.4x | 0.4x |
Sat, 04 Mar 2023 | HK$325.7b | HK$782.5b | HK$3.5b | 16.5x | 92.7x | 0.4x |
Mon, 30 Jan 2023 | HK$316.4b | HK$793.5b | HK$3.5b | 16.3x | 90.9x | 0.4x |
Wed, 28 Dec 2022 | HK$288.6b | HK$771.8b | HK$3.0b | 13.8x | 95.5x | 0.4x |
Fri, 25 Nov 2022 | HK$257.0b | HK$752.2b | HK$2.2b | 13x | 115.9x | 0.3x |
Sun, 23 Oct 2022 | HK$199.3b | HK$656.8b | -HK$2,280,316,840.00 | 13.6x | -87.4x | 0.3x |
Tue, 20 Sep 2022 | HK$204.4b | HK$678.6b | -HK$2,453,227,237.00 | 16.6x | -83.3x | 0.3x |
Thu, 18 Aug 2022 | HK$220.8b | HK$688.6b | -HK$4,569,851,837.00 | 17.3x | -48.3x | 0.3x |
Sat, 16 Jul 2022 | HK$238.1b | HK$691.2b | -HK$6,926,833,919.00 | 17.6x | -34.4x | 0.3x |
Mon, 13 Jun 2022 | HK$213.4b | HK$693.2b | -HK$6,126,784,825.00 | 17.1x | -34.8x | 0.3x |
Wed, 11 May 2022 | HK$190.2b | HK$680.2b | -HK$6,811,349,977.00 | 16.7x | -27.9x | 0.3x |
Fri, 08 Apr 2022 | HK$202.3b | HK$718.2b | -HK$7,191,122,221.00 | 17.8x | -28.1x | 0.3x |
Sun, 06 Mar 2022 | HK$241.5b | HK$722.3b | -HK$5,039,379,043.00 | 15.9x | -47.9x | 0.3x |
Tue, 01 Feb 2022 | HK$239.4b | HK$715.2b | -HK$5,279,388,416.00 | 17.5x | -45.3x | 0.3x |
Thu, 30 Dec 2021 | HK$245.5b | HK$712.3b | -HK$5,430,575,220.00 | 17.9x | -45.2x | 0.3x |
Sat, 27 Nov 2021 | HK$292.9b | HK$710.1b | -HK$5,418,761,564.00 | 18.1x | -54.1x | 0.4x |
Mon, 25 Oct 2021 | HK$328.1b | HK$698.4b | -HK$5,406,879,775.00 | 16.9x | -60.7x | 0.5x |
Wed, 22 Sep 2021 | HK$311.1b | HK$690.5b | -HK$5,423,838,888.00 | 16.7x | -57.4x | 0.5x |
Fri, 20 Aug 2021 | HK$390.8b | HK$689.6b | -HK$5,408,746,530.02 | 16.4x | -72.3x | 0.6x |
-72.3x
Which industries have driven the changes within the Hong Kong Healthcare industry?
HK Market | -0.15% | |
Healthcare | 2.24% | |
Healthcare Services | -1.36% | |
Healthcare Distributors | 3.48% | |
Managed Healthcare | 0% | |
Healthcare Services | -0.87% | |
Healthcare Facilities | -10.95% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
1099 Sinopharm Group | HK$20.20 | 7.8% +HK$4.6b | -5.4% | PE6.5x | |
874 Guangzhou Baiyunshan Pharmaceutical Holdings | HK$20.15 | 3.5% +HK$1.1b | -8.2% | PE7.3x | |
2273 Gushengtang Holdings | HK$35.20 | 5.9% +HK$473.1m | -15.1% | PE31.2x | |
1951 Jinxin Fertility Group | HK$2.60 | 5.3% +HK$357.3m | -36.7% | PE19.1x | |
383 Tian An Medicare | HK$1.00 | 33.3% +HK$271.5m | 14.9% | PE34.3x |